Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12605000648628
Ethics application status
Approved
Date submitted
7/10/2005
Date registered
17/10/2005
Date last updated
17/10/2005
Type of registration
Prospectively registered

Titles & IDs
Public title
Is Homatropine 5% effective in reducing pain associated with corneal abrasion when compared to placebo?
Scientific title
Is Homatropine 5% effective in reducing pain associated with corneal abrasion when compared to placebo?
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Corneal Abrasion 781 0
Condition category
Condition code
Eye 855 855 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study will be a double blind randomised controlled trial with parallel groups receiving either the active agent (homatropine 5% eye drop).
Intervention code [1] 704 0
None
Comparator / control treatment
Placebo (hypromellose 0.5% eye drop) for a period of 24 hours.
Control group
Placebo

Outcomes
Primary outcome [1] 1097 0
The main outcome measure is the measurement of pain on the visual analogue scale (VAS) score
Timepoint [1] 1097 0
At 0, 6, 12, 18 and 24 hours after administration of the randomised eye drop.
Secondary outcome [1] 2032 0
None
Timepoint [1] 2032 0

Eligibility
Key inclusion criteria
Corneal abrasion or ulceration from trauma (any cause, excluding chemical burn), defined as visualisation of fluorescein uptake on slit lamp examination, patient must have not undergone any prior eye examination/intervention and/or received topical therapies to the eye within 48 hours before the injury.
Minimum age
18 Years
Maximum age
Not stated
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Non-traumatic Corneal Ulceration such as flash burn, suspected viral or other infection, patients less than 18 years old, pregnancy, breastfeeding mothers, allergy to any medications involved in the study, glaucoma, bilateral abrasion, patients who cannot read and/or understand the patient information for whatever reason or are unwilling to give consent to participate, keratoconus.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sixty opaque envelopes will be prepared and numbered one to sixty. These will be in the possession of an independent pharmacist who will then prepare the bottles of study medication. The independent pharmacist will have no active or ongoing involvement in the conduct of the study after initial preparation of the study medications.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A pharmacist independent to the study will generate a random number sequence (from one to sixty) using a random number table from a standard textbook (Geigy Scientific Tables, Vol. 2. 8th edn. Ciba-Geigy Ltd.) to randomise the order for use of either the homatropine 5% eye drops or the hypromellose 0.5% eye drops. The first thirty random numbers will be allocated to the homatropine 5% group and the remaining thirty random numbers will be allocated to the hypomellose 0.5% group.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/12/2005
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 941 0
Government body
Name [1] 941 0
Southern Health
Country [1] 941 0
Australia
Primary sponsor type
Government body
Name
Southern Health
Address
Country
Australia
Secondary sponsor category [1] 801 0
None
Name [1] 801 0
n/a
Address [1] 801 0
Country [1] 801 0

Ethics approval
Ethics application status
Approved

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 36014 0
Address 36014 0
Country 36014 0
Phone 36014 0
Fax 36014 0
Email 36014 0
Contact person for public queries
Name 9893 0
Andy Sullivan
Address 9893 0
Pharmacy Department
Dandenong Hospital
David Street
Dandenong VIC 3175
Country 9893 0
Australia
Phone 9893 0
+61 3 95548191
Fax 9893 0
Email 9893 0
[email protected]
Contact person for scientific queries
Name 821 0
Dr. Robert Meek
Address 821 0
Emergency Department
Dandenong Hospital
David Street
Dandenong VIC 3175
Country 821 0
Australia
Phone 821 0
+61 3 95548177
Fax 821 0
+61 3 95548453
Email 821 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.